QLINEA Share Price Performance
SEK 16.45
-30.85 (-65.22%)
79.4% undervalued intrinsic discount
SEK 80.00
Fair Value
Price SEK 16.45
AnalystLowTarget SEK 80.00
AnalystConsensusTarget SEK 53.00
Fair ValueSEK 80.00
Share Pricen/a
Q-linea AB (publ) Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
QLINEA Community Narratives
AN
Fair Value
·Fair Value SEK 80 79.4% undervalued intrinsic discount
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value SEK 53 69.0% undervalued intrinsic discount
Overvaluation Will Persist As Italy And US Markets Evolve
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Overvaluation Will Persist As Italy And US Markets Evolve
Key Takeaways Growth and profitability assumptions rely on optimistic adoption rates and premium pricing, both threatened by slow expansions, budget constraints, and rising competition. High R&D costs, cash burn, and buyer bargaining power risk limiting future margin expansion, increasing dilution, and depressing earnings expectations.Read more
AN
SEK 53
69.0% undervalued intrinsic discount
Fair Value
Profit Margin
8.09%
Future PE
17.29x
Price in 2029
SEK 31.14
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
Key Takeaways Growth drivers include increased clinical adoption and market mandates, but long sales cycles, regulatory delays, and volatile demand hinder consistent revenue and market share gains. Intensifying competition, escalating R&D costs, and budget constraints threaten profitability, recurring revenue streams, and the effective utilization of Q-linea's installed platforms.Read more
AN
SEK 80
79.4% undervalued intrinsic discount
Fair Value
Profit Margin
8.7%
Future PE
25.14x
Price in 2028
SEK 47.02
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
QLINEA: New Hospital Contracts And Equity Raise Will Support Future Upside
Fair Value: SEK 53 69.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Slow Integration And Competition Will Hinder Revenue With Emerging Promise
Fair Value: SEK 80 79.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Q-linea AB (publ) Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Oct 30, 2026
- -8.05
- 50.03%
- -1,056.14%
- 4.3%
About QLINEA
- Founded
- 2007
- Employees
- 70
- CEO
- WebsiteView website
Q-linea AB (publ) engages in the manufacturing and sale of instruments and consumables diagnose and treat infectious diseases in the United Kingdom, the United States, France, the Middle East, Belgium, Italy, and Finland. It offers ASTar, an antimicrobial susceptibility testing (AST) technology used in the treatment of bloodstream infections and sepsis; and ASTar BC G- Kit which contains two disposables, including a sample preparation cartridge and an AST disc, used with the Frozen insert. The company also develops Podler, a portable blood culture technology. It serves physicians, hospitals, laboratories, healthcare payers, and the medical profession. The company was incorporated in 2007 and is headquartered in Uppsala, Sweden.
